Clicky

Aprea Therapeutics, Inc.(APRE)

Description: Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.


Keywords: Cancer Biopharmaceutical Tumor Clinical Development Acute Myeloid Leukemia Myelodysplastic Syndrome Cancer Therapies Lactams Syndromes P53 Triazines Tumor Suppressor Genes Anti Cancer Therapies Azacitidine Nucleosides Tumor Suppressor

Home Page: atrinpharma.com

APRE Technical Analysis

535 Boylston St.
Boston, MA 02116
United States
Phone: 617-463-9385


Officers

Name Title
Mr. Christian S. Schade Chairman & CEO
Dr. Oren Gilad Ph.D. Co-Founder, Pres & Director
Mr. Scott M. Coiante Sr. VP, CFO & Sec.
Dr. Gregory A. Korbel Ph.D. Sr. VP & COO
Dr. Dansu Li Ph.D. Head of Technology
Dr. Lars B. Abrahmsen Ph.D. Sr. VP & Chief Scientific Officer
Dr. Rifat Pamukcu M.D. Chief Medical Advisor & Director
Mr. Hank Breslin Head of Medicinal Chemistry
Dr. Michel Afargan Ph.D. Head of Pharmacology Devel.
Ms. Andrea Epstein Controller

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.0351
Price-to-Sales TTM: 0
IPO Date: 2019-10-03
Fiscal Year End: December
Full Time Employees: 0
Back to stocks